期刊文献+

肼苯哒嗪对大肠癌Lovo细胞及RUNX-3基因的影响

Effect of Hydralazine on the Proliferation of Colorectal Cancer Lovo Cells and Expression of RUNX-3 Gene
原文传递
导出
摘要 目的:观察肼苯哒嗪对大肠癌Lovo细胞增殖作用的影响,探讨肼苯哒嗪对大肠癌Lovo细胞中抑癌基因RUNX-3的转录调节作用及其对细胞生长和凋亡的影响。方法:应用不同浓度(0,10,20,40,80,160μmol/L)的肼苯哒嗪,于不同作用时间(24,48,72,96h)处理人大肠癌Lovo细胞,采用四甲基偶氮唑蓝(MTT)法测定肼苯哒嗪作用下Lovo细胞的生存率,倒置显微镜观察细胞的形态学变化;采用RT-PCR法检测肼苯哒嗪对RUNX-3 mRNA表达的影响。结果:①不同药物浓度组在同一作用时间下,细胞生存率差异有统计学意义(P<0.05);同一药物浓度不同作用时间组之间(24-96h)的细胞生存率无统计学意义(P>0.05);②RUNX-3 mRNA在大肠癌Lovo细胞中的表达随浓度的增加而增强。结论:肼苯哒嗪有抑制人大肠癌Lovo细胞生长的作用,抑制作用呈浓度依赖性;可以促进RUNX-3 mRNA的表达,从而促进大肠癌Lovo细胞的凋亡。 Objective:To investigate the effect of hydralazine on the growth of human colorectal cancer Lovo cells and the transcription of the RUNX-3 gene in Lovo cells. Methods: Human colorectal cancer Lovo cells were treated by hydralazine at different concentrations (0, 10, 20, 40, 80, and 160 μmol/L) respectively at different time (24, 48, 72, and 96 hours respectively). The growth rate of the cells was detected by MTT assay. The expression of RUNX-3 mRNA was analyzed by RT-PCR. Results: ①The proliferation of Lovo cells was inhibited by hydralazine at concentrations of 10-160 μmol/L in a concentration-dependent manner in stead of time-dependent manner (P0.05). ②The expression of RUNX-3 mRNA was up-regulated as the concentration increased. Conclusion: Hydralazine can inhibit the proliferation of Lovo cells and promote the expression of RUNX-3 mRNA in a concentration-dependent manner (10-160 μmol/L).
作者 张建宝 邓涛
出处 《武汉大学学报(医学版)》 CAS 北大核心 2010年第2期220-222,226,共4页 Medical Journal of Wuhan University
关键词 肼苯哒嗪 大肠癌LOVO细胞 RUNX-3基因 Hydralazine Colorectal Cancer Lovo Cells RUNX 3 Gene
  • 相关文献

参考文献9

  • 1Bangsow C, Rubins N,Glusman G, et al. The RUNX3 gene-sequence, structure and regulated expression[J]. Gene, 2001,279(2) :221-232.
  • 2Deng T,Zhang Y. Possible involvement of activation of P53/P21 and demethylation of RUNX 3 in the cytotoxicity against Lovo cells induced by 5-Aza-2'-deoxycytidine[J]. Life Sciences, 2009,84: 311-320.
  • 3Cheng JC, Weisenberger DJ, Gonzales FA, et al. Jones PA Continuous zebularine treatment effectively sustains demethylation in human bladder cancer cells [J]. Mol Cell Biol,2004,24(3):1 270-1 278.
  • 4Cheng JC, Matsen CB, Gonzales FA, et al. Inhibition of DNA methylation and reactivation of silenced genes by zebalarine[J]. Natl Cancer Inst,2003,95(5):399-409.
  • 5Lee G, Wolff E, Miller JH. Mutagenicity of the cytidine analog zebularine in Eseherichia coli[J]. DNA Repair (Arnst) ,2004,3:155-161.
  • 6Santini V, Kantarjian HM, Issa JP. Changes in DNA methylation in neoplasia: Pathophysiology and therapeutic implications [J]. Ann Intern Med, 2001,134: 573-586.
  • 7Chavez BA, Perez PC, Perez CE, et al. Antineoplastie effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in carcinoma cell lines[J]. Carcinoma Cell, 2006, 6:2.
  • 8Candelaria M, Gallardo RD, Arce C, et al. A phase Ⅱ study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors[J]. Annals of Oncology, 2007, 18 (9):1 529-1 538.
  • 9Song YH,Zhang CJ. Hydralazine inhibits human cervical cancer cell growth in vitro in association with APC demethylation and re-expression[J]. Cancer Chemother Pharmacol, 2009, 63:605-613.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部